Vista Pharmaceuticals (524711) Q4 97/98 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 97/98 earnings summary
29 Oct, 2026Executive summary
FY98 total income Rs41.08 lakh vs Rs27.62 lakh in FY97; net loss narrowed to Rs63.05 lakh from Rs92.79 lakh.
Accumulated losses rose to Rs254.66 lakh from Rs187.84 lakh.
Financial highlights
Export turnover Rs43.51 lakh; total expenditure Rs104.13 lakh vs Rs120.41 lakh in FY97.
Depreciation was Rs30.24 lakh vs Rs28.10 lakh; financial charges were Rs4.25 lakh vs Rs4.11 lakh.
No income-tax provision was made because no taxable income was computed.
Outlook and guidance
FY98 US pharmaceutical exports were reported at Rs45.30 lakh; FY99 export target was Rs1–2 crore.
Target markets included Latin America, Southeast Asia, the Middle East and Africa.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Vista Pharmaceuticals
- Export growth strengthened, but reported losses and financing risks remained significant.524711
Q4 98/99 - Exports grew, but financing costs and accounting changes deepened the loss.524711Q4 99/00
- Exports fell as losses deepened, while heavy interest and uninstalled plant constrained recovery.524711Q4 01/02
- Higher exports could not offset heavy finance costs and mounting losses.524711Q4 02/03
- Working-capital strain and debt defaults overshadowed a Rs. 180 lakh sales outlook.524711Q4 03/04
- A Rs 3.38 crore loss and Rs 1,991.66 lakh IDBI default drove a proposed funding issue.524711Q4 04/05
- FY06 profit hinged on exceptional IDBI waivers as debt settlement and facility upgrades reset operations.524711Q4 05/06
- FY07 loss widened as expansion progressed toward US generic production.524711Q4 06/07
- Loss widened as expansion spending advanced and Bactrim Generic awaited US FDA approval.524711Q4 07/08